Cargando…
Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, mo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745994/ https://www.ncbi.nlm.nih.gov/pubmed/29299229 http://dx.doi.org/10.1186/s13569-017-0086-2 |
_version_ | 1783289021109108736 |
---|---|
author | Provenzano, Salvatore Raimondi, Alessandra Bertulli, Rossella M. Colia, Vittoria Renne, Salvatore L. Collini, Paola Dagrada, Gianpaolo Callegaro, Dario Fiore, Marco Greco, Francesca G. Casali, Paolo G. |
author_facet | Provenzano, Salvatore Raimondi, Alessandra Bertulli, Rossella M. Colia, Vittoria Renne, Salvatore L. Collini, Paola Dagrada, Gianpaolo Callegaro, Dario Fiore, Marco Greco, Francesca G. Casali, Paolo G. |
author_sort | Provenzano, Salvatore |
collection | PubMed |
description | BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, most often marked by translocation of PHF1 gene. Surgery is the mainstay of treatment and proves usually curative, although, in rarer cases the disease shows malignant features and tendency to recur both locally and at distant sites. In such cases, no standard treatment exists. CASE PRESENTATION: We report on a case of malignant advanced OFMT of the hand with lung metastases responding to isolated limb perfusion with human recombinant tumor necrosis factor and melphalan and chemotherapy with epirubicin and ifosfamide. CONCLUSIONS: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in advanced OFMT. |
format | Online Article Text |
id | pubmed-5745994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57459942018-01-03 Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor Provenzano, Salvatore Raimondi, Alessandra Bertulli, Rossella M. Colia, Vittoria Renne, Salvatore L. Collini, Paola Dagrada, Gianpaolo Callegaro, Dario Fiore, Marco Greco, Francesca G. Casali, Paolo G. Clin Sarcoma Res Case Report BACKGROUND: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermediate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremities. It is now established that it is a translocation related tumor, most often marked by translocation of PHF1 gene. Surgery is the mainstay of treatment and proves usually curative, although, in rarer cases the disease shows malignant features and tendency to recur both locally and at distant sites. In such cases, no standard treatment exists. CASE PRESENTATION: We report on a case of malignant advanced OFMT of the hand with lung metastases responding to isolated limb perfusion with human recombinant tumor necrosis factor and melphalan and chemotherapy with epirubicin and ifosfamide. CONCLUSIONS: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in advanced OFMT. BioMed Central 2017-12-28 /pmc/articles/PMC5745994/ /pubmed/29299229 http://dx.doi.org/10.1186/s13569-017-0086-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Provenzano, Salvatore Raimondi, Alessandra Bertulli, Rossella M. Colia, Vittoria Renne, Salvatore L. Collini, Paola Dagrada, Gianpaolo Callegaro, Dario Fiore, Marco Greco, Francesca G. Casali, Paolo G. Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title | Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title_full | Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title_fullStr | Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title_full_unstemmed | Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title_short | Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
title_sort | response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745994/ https://www.ncbi.nlm.nih.gov/pubmed/29299229 http://dx.doi.org/10.1186/s13569-017-0086-2 |
work_keys_str_mv | AT provenzanosalvatore responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT raimondialessandra responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT bertullirossellam responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT coliavittoria responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT rennesalvatorel responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT collinipaola responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT dagradagianpaolo responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT callegarodario responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT fioremarco responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT grecofrancescag responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor AT casalipaolog responsetoisolatedlimbperfusionandchemotherapywithepirubicinplusifosfamideinametastaticmalignantossifyingfibromyxoidtumor |